Non-proportional hazards and applications in immuno-oncology

Add to:

Designs of clinical trials with time to event primary endpoints usually rely on hazards being constant over time. A major challenge in immuno-oncology is the delayed onset of benefit with such therapies and the presence of non-proportional hazards. The impact of this needs to be accounted for in sample size calculations, analysis methodology and reporting. At this meeting, we will examine possible strategies to handle such features, which may not be fully known when the trial is initiated.

NonPH draft agenda 20Jan20
Member cost = £40 + VAT 
Non-Member cost = £135 + VAT and includes PSI Membership for 2020.

Click here to register your place on the course.

Upcoming Events

Latest Jobs